EchoGo® Heart Failure vs SignalHF
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, EchoGo® Heart Failure, is designed for the diagnosis of Heart Failure with preserved Ejection Fraction (HFpEF) through the analysis of echocardiograms. In contrast, Tool B, SignalHF, focuses on predicting heart failure hospitalizations within 30 days by analyzing data from cardiac implantable electronic devices. While both address heart failure, their distinct data sources and clinical objectives make them suitable for different stages of patient care: diagnosis versus proactive hospitalization prevention.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Heart Failure is designed to analyze routine echocardiograms to detect Heart Failure with preserved Ejection Fraction (HFpEF), providing insights to support clinical decisions. SignalHF, on the other hand, is an AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices (CIEDs).
EchoGou00ae Heart Failure analyzes routine echocardiogram video clips to identify patterns consistent with HFpEF. SignalHF analyzes physiological data, demographics, lead measurements, episodes, and therapies collected from cardiac implantable electronic devices such as pacemakers, ICDs, and CRTs.
EchoGou00ae Heart Failure delivers insights within 20 minutes and generates automated structured reports with DICOM workflow for delivery to PACS, integrating seamlessly with existing IT stacks. SignalHF generates automatic alerts for care teams based on risk scores and offers a unified platform for centralizing cardiac implantable device data, enabling early intervention and personalized care plans.
EchoGou00ae Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis, and is covered by Medicare and select commercial insurers. For SignalHF, pricing details are not specified, and no specific reimbursement information is provided in the available facts.
EchoGou00ae Heart Failure is clinically validated with 90% sensitivity and 86% specificity for HFpEF detection. SignalHF is an FDA-cleared AI algorithm for heart failure prediction, but specific sensitivity or specificity metrics are not detailed in the provided information.
EchoGou00ae Heart Failure is designed for Cardiology, Emergency Medicine, and Internal Medicine specialties. SignalHF is primarily focused on Cardiology.